Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced it has signed an autoantibody profiling collaboration with a leading global biopharmaceutical company with extensive experience in developing novel
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has noted the national ITV News1 feature last weekend on Oncimmune’s EarlyCDT® Lung blood test titled “New Blood Test Provides Breakthrough in Lung
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the presentation of two further abstracts connected to the Early detection of Cancer of the Lung Scotland (“ECLS”) trial.
Oncimmune Holdings plc (LON:ONC.L), the leading global immunodiagnostics group, has announced that The European Respiratory Journal – a leading lung disease focused scientific publication and flagship journal of the European Respiratory Society
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group,has announced that Roche has exercised its option to increase the scope and value of the cornerstone contract announced on 28 May
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has noted the publication of research, supported by its ImmunoINSIGHTS team, in Arthritis Research & Therapy1, entitled ‘Profiling IgG antibodies targeting unmodified and
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced that its distributor in Brazil, Valentech International LLC , has obtained marketing authorisation for the EarlyCDT Lung blood test
Positive outcomes following the UK’s National Institute for Health and Care Excellence (NICE) review of Oncimmune Holdings (LON:ONC) EarlyCDT Lung diagnostic test, provides clear external validation for its incorporation into
Oncimmune Holdings plc (LON:ONC), a leading global immunodiagnostics group, has today announced the appointment of Professor Tariq Sethi as Chief Scientific Officer, Matthew Luttrell as Chief Commercial Officer and Cléa Rosenfeld
Oncimmune Holdings PLC (LON:ONC), a leading global immunodiagnostics group, today announced that it has secured a credit facility of €8.5 million with IPF Management SA. Under the terms of the
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
